FMC (FMC) Q1 2026 Earnings Call Transcript

FMC delivered Q1 revenue of $762 million and EBITDA of $72 million, both ahead of guidance, but reiterated a softer 2026 outlook with full-year sales of $3.6 billion-$3.8 billion, EBITDA of $670 million-$730 million, and adjusted EPS of $1.63-$1.89. Management highlighted higher debt at $4.5 billion gross, negative Q1 free cash flow of $628 million, and ongoing headwinds from lower diamide partner sales, India divestiture, tariffs, and Iran-related cost uncertainty. Offsetting that, the company is advancing $1 billion of asset sales/debt reduction, secured EU approval for Isoflex, and expects second-half volume recovery driven by new active ingredients and stronger Brazil orders.

Analysis

The market is pricing FMC as a balance-sheet repair story, but the bigger second-order effect is that management is deliberately shrinking low-quality revenue while trying to reconstitute mix around higher-margin, self-help assets. That usually looks ugly in the next 1-2 quarters, yet it can be disproportionately positive for creditors and convertibility of cash flow if the asset-sale pipeline closes on schedule. The new secured structure matters less as a financing event than as a constraint: it effectively forces execution on disposals and licensing, which reduces near-term dilution risk but raises the bar for operational delivery.

The key swing factor is not the headline revenue trough; it is whether the new active ingredients and Rynaxypyr repositioning can offset the partner decline before the 2027 manufacturing savings arrive. If Brazil order momentum and EU Isoflex timing stay intact, FMC can create a cleaner earnings inflection into late 2026/2027 with less dependency on legacy diamides. If not, leverage remains the dominant equity overhang because interest expense is now absorbing much of the operating leverage that would otherwise show up in EPS.

Consensus appears to be underestimating how much of the near-term equity story is actually a credit story. A successful India sale plus one licensing upfront could materially de-risk the capital structure even if reported EPS stays weak, which means the stock could rerate before the income statement recovers. The contrarian risk is that a weak Brazil season or delayed registration on the new products would expose the company to a negative loop: lower cash flow, higher relative leverage, tighter customer liquidity, and less room to defend pricing. In that scenario, the equity becomes a levered call option on asset monetization rather than on operations.

Key Decisions for Investors

• Prefer FMC equity only as a tactical event-driven long after confirmation of the India sale signing; entry on a pullback is justified only if the deal closes and net debt starts to trend lower. Target a 3-6 month horizon with upside tied to multiple expansion rather than EPS growth.
• Pair trade: long FMC / short a broad ag-input basket or weaker crop-input peers over 6-9 months, on the view that FMC has the clearest self-help catalyst stack (asset sales, manufacturing migration, product launches). Use a tight stop if Brazil orders or H2 sell-in roll over.
• Buy FMC bonds or CDS protection selectively instead of common equity if seeking exposure to the deleveraging story; the secured covenant and asset-sale path improve downside protection more than they improve near-term EPS. Best risk/reward is in the capital structure, not the stock.
• If trading equity optionality, consider a call spread into the next earnings/update cycle, as the rerating trigger is likely a combination of signed divestitures and improved H2 visibility rather than current-quarter fundamentals. Avoid naked calls because execution risk is binary and timing-sensitive.
• Watch for any sign of delayed asset monetization or weaker Brazil order conversion; that would be the signal to short FMC on a 1-2 quarter horizon, because the market will quickly reprice the company back to a stressed-leverage narrative.